These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 28249963)

  • 1. Cell death response to anti-mitotic drug treatment in cell culture, mouse tumor model and the clinic.
    Shi J; Mitchison TJ
    Endocr Relat Cancer; 2017 Sep; 24(9):T83-T96. PubMed ID: 28249963
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Kinesin motor proteins as targets for cancer therapy.
    Huszar D; Theoclitou ME; Skolnik J; Herbst R
    Cancer Metastasis Rev; 2009 Jun; 28(1-2):197-208. PubMed ID: 19156502
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cell type variation in responses to antimitotic drugs that target microtubules and kinesin-5.
    Shi J; Orth JD; Mitchison T
    Cancer Res; 2008 May; 68(9):3269-76. PubMed ID: 18451153
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting mitosis for anti-cancer therapy.
    Sudakin V; Yen TJ
    BioDrugs; 2007; 21(4):225-33. PubMed ID: 17628120
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How do anti-mitotic drugs kill cancer cells?
    Gascoigne KE; Taylor SS
    J Cell Sci; 2009 Aug; 122(Pt 15):2579-85. PubMed ID: 19625502
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mitotic drug targets and the development of novel anti-mitotic anticancer drugs.
    Schmidt M; Bastians H
    Drug Resist Updat; 2007; 10(4-5):162-81. PubMed ID: 17669681
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel anti-microtubule agent with carbazole and benzohydrazide structures suppresses tumor cell growth in vivo.
    Ohira M; Iwasaki Y; Tanaka C; Kuroki M; Matsuo N; Kitamura T; Yukuhiro M; Morimoto H; Pang N; Liu B; Kiyono T; Amemiya M; Tanaka K; Yoshida K; Sugimoto N; Ohshima T; Fujita M
    Biochim Biophys Acta; 2015 Sep; 1850(9):1676-84. PubMed ID: 25960391
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Post-slippage multinucleation renders cytotoxic variation in anti-mitotic drugs that target the microtubules or mitotic spindle.
    Zhu Y; Zhou Y; Shi J
    Cell Cycle; 2014; 13(11):1756-64. PubMed ID: 24694730
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of new cancer therapeutic agents targeting mitosis.
    Miglarese MR; Carlson RO
    Expert Opin Investig Drugs; 2006 Nov; 15(11):1411-25. PubMed ID: 17040200
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mitotic drug targets.
    Kaestner P; Bastians H
    J Cell Biochem; 2010 Oct; 111(2):258-65. PubMed ID: 20518069
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibitors targeting mitosis: tales of how great drugs against a promising target were brought down by a flawed rationale.
    Komlodi-Pasztor E; Sackett DL; Fojo AT
    Clin Cancer Res; 2012 Jan; 18(1):51-63. PubMed ID: 22215906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advances in mitotic inhibitors for cancer treatment.
    Jiang N; Wang X; Yang Y; Dai W
    Mini Rev Med Chem; 2006 Aug; 6(8):885-95. PubMed ID: 16918495
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An update on the developing mitotic inhibitors for the treatment of non-small cell carcinoma.
    Sacco PC; Gridelli C
    Expert Opin Emerg Drugs; 2017 Sep; 22(3):213-222. PubMed ID: 28836854
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging mitotic inhibitors for non-small cell carcinoma.
    Casaluce F; Sgambato A; Maione P; Ciardiello F; Gridelli C
    Expert Opin Emerg Drugs; 2013 Mar; 18(1):97-107. PubMed ID: 23448156
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antimitotic drugs in cancer chemotherapy: promises and pitfalls.
    Marzo I; Naval J
    Biochem Pharmacol; 2013 Sep; 86(6):703-10. PubMed ID: 23886991
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-mitotic agents: Are they emerging molecules for cancer treatment?
    Penna LS; Henriques JAP; Bonatto D
    Pharmacol Ther; 2017 May; 173():67-82. PubMed ID: 28174095
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Spindle poisons and cell fate: a tale of two pathways.
    Matson DR; Stukenberg PT
    Mol Interv; 2011 Apr; 11(2):141-50. PubMed ID: 21540474
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor-Associated Macrophages Suppress the Cytotoxic Activity of Antimitotic Agents.
    Olson OC; Kim H; Quail DF; Foley EA; Joyce JA
    Cell Rep; 2017 Apr; 19(1):101-113. PubMed ID: 28380350
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cell cycle-dependent cytotoxicity and mitotic spindle checkpoint dependency of investigational and approved antimitotic agents.
    Birk M; Bürkle A; Pekari K; Maier T; Schmidt M
    Int J Cancer; 2012 Feb; 130(4):798-807. PubMed ID: 21387302
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mitosis inhibitors in anticancer therapy: When blocking the exit becomes a solution.
    Henriques AC; Ribeiro D; Pedrosa J; Sarmento B; Silva PMA; Bousbaa H
    Cancer Lett; 2019 Jan; 440-441():64-81. PubMed ID: 30312726
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.